KRYS - Krystal Biotech Inc logo

KRYS

Krystal Biotech Inc

Rev โ€”top 1%5Y
Hold

Krystal Biotech develops genetic medicines for severe diseases, focusing on treatments with high unmet needs in the U.S. Its product VYJUVEK targets dystrophic epidermolysis bullosa. The company also has multiple therapies in clinical development for various conditions.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$5,916today

Score Overview

1 Year
Score
Net Growth17.88%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth13.20%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth447.08%
Net Trend80%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend80%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth32x
Net Trend44%
Net Income Consistency
Rev Growthโ€”
Rev Trend56%
Revenue Consistency

See the full market ranking โ†’

Krystal Biotech Inc fundamental performance

Across Krystal Biotech Inc's full reported history, from 2017 to 2025, revenue grew from $ 0.00 to $ 389M and net income went from -$ 7M to $ 204M. Revenue increased in 56% of the years measured; net income in 44%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 332.86โ€”
1 Year2025-08-12
$ 143.62131.76%
5 Years2021-08-12
$ 56.26491.65%
All Time2017-09-20
$ 10.6431x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 440M$ 241M$ 845M
2025$ 389M$ 204M$ 827M
2024$ 290M$ 89M$ 597M
2023$ 50M$ 10M$ 532M
2022$ 0.00-$ 139M$ 379M
2021$ 0.00-$ 69M$ 438M
2020$ 0.00-$ 32M$ 271M
2019$ 0.00-$ 19M$ 193M
2018$ 1M-$ 10M$ 111M
IPO2017$ 0.00-$ 7M$ 49M

Explore beyond KRYS

You're looking at Krystal Biotech Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies